Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Leonard Chapman sold 1,664 shares of the business's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $145.55, for a total transaction of $242,195.20. Following the completion of the sale, the chief executive officer now directly owns 198,365 shares in the company, valued at $28,872,025.75. This trade represents a 0.83 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Steven Leonard Chapman also recently made the following trade(s):
- On Monday, March 31st, Steven Leonard Chapman sold 9,563 shares of Natera stock. The shares were sold at an average price of $138.41, for a total value of $1,323,614.83.
- On Monday, March 17th, Steven Leonard Chapman sold 6,702 shares of Natera stock. The stock was sold at an average price of $146.03, for a total value of $978,693.06.
- On Wednesday, March 5th, Steven Leonard Chapman sold 87,272 shares of Natera stock. The stock was sold at an average price of $143.40, for a total value of $12,514,804.80.
- On Wednesday, January 29th, Steven Leonard Chapman sold 13,685 shares of Natera stock. The shares were sold at an average price of $165.87, for a total transaction of $2,269,930.95.
- On Wednesday, January 22nd, Steven Leonard Chapman sold 78,553 shares of Natera stock. The shares were sold at an average price of $164.97, for a total transaction of $12,958,888.41.
Natera Trading Down 0.4 %
Shares of Natera stock traded down $0.69 during trading on Friday, reaching $153.79. 806,941 shares of the company were exchanged, compared to its average volume of 1,377,779. Natera, Inc. has a twelve month low of $87.20 and a twelve month high of $183.00. The business has a 50-day moving average price of $148.26 and a 200-day moving average price of $153.19. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $20.79 billion, a price-to-earnings ratio of -87.38 and a beta of 1.80.
Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $476.10 million during the quarter, compared to analysts' expectations of $447.91 million. Sell-side analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.
Institutional Investors Weigh In On Natera
Several hedge funds have recently bought and sold shares of NTRA. Vanguard Group Inc. lifted its holdings in Natera by 7.7% during the fourth quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock worth $1,949,697,000 after acquiring an additional 879,463 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Natera by 134.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock worth $1,067,327,000 after purchasing an additional 3,871,862 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Natera by 43.7% during the 4th quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock valued at $1,060,836,000 after purchasing an additional 2,036,396 shares in the last quarter. Wellington Management Group LLP raised its holdings in Natera by 15.7% during the 4th quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock worth $512,898,000 after buying an additional 439,778 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Natera by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company's stock valued at $355,809,000 after buying an additional 142,201 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
NTRA has been the subject of a number of research analyst reports. Morgan Stanley lifted their target price on shares of Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Sanford C. Bernstein increased their target price on Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a report on Friday, January 10th. StockNews.com raised Natera from a "sell" rating to a "hold" rating in a report on Wednesday, March 19th. Piper Sandler increased their price objective on shares of Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. Finally, Royal Bank of Canada started coverage on shares of Natera in a research note on Thursday, March 13th. They issued an "outperform" rating and a $251.00 target price for the company. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $175.76.
View Our Latest Stock Report on NTRA
About Natera
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
See Also
Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
